Efficacy analysis of MASTERKEY-265 phase 1b study of talimogene laherparepvec (T-VEC) and pembrolizumab (pembro) for unresectable stage IIIB-IV melanoma.

Georgina V. Long, F. Stephen Hodi, Olivier Michielin et al.|Journal of Clinical Oncology|2016

Cited by 110